Claims for Patent: 11,219,626

Summary for Patent: 11,219,626

Title:	Pharmaceutical compositions comprising meloxicam
Abstract:	Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Inventor(s):	Herriot Tabuteau
Assignee:	Axsome Therapeutics Inc
Application Number:	US17/122,618
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,219,626
Patent Claims:	1. A method of treating migraine, comprising administering an oral dosage form comprising an inclusion complex of sulfobutyl ether β-cyclodextrin (SBEβCD) with about 15 mg to about 25 mg of a meloxicam, about 400 mg to about 600 mg of sodium bicarbonate, and about 8 mg to about 13 mg of a rizatriptan to a human being suffering from migraine; wherein the Tmax of meloxicam in the human being after administering the oral dosage form is shorter than the Tmax of meloxicam that would result from orally administering a reference dosage form comprising a) the same amount of the meloxicam; b) no rizatriptan; c) no SBEβCD; and d) no bicarbonate; and wherein the human being achieves a reduction in migraine pain that lasts for about 8 hours to about 24 hours. 2. The method of claim 1, wherein about 10 mg of the rizatriptan is present in the oral dosage form based upon the weight of the rizatriptan in the free base form. 3. The method of claim 2, wherein the rizatriptan is present in a salt form in an amount that is a molar equivalent of about 10 mg of the rizatriptan in the free base form. 4. The method of claim 3, wherein the rizatriptan is present as rizatriptan benzoate. 5. The method of claim 1, wherein the oral dosage form contains about 15 mg of the meloxicam. 6. The method of claim 1, wherein the oral dosage form contains about 20 mg of the meloxicam. 7. The method of claim 1, wherein the oral dosage form contains about 100 mg to about 175 mg of the SBEβCD. 8. The method of claim 1, wherein the oral dosage form contains about 100 mg to about 140 mg of the SBEβCD. 9. The method of claim 1, wherein the oral dosage form contains about 500 mg of sodium bicarbonate. 10. The method of claim 1, wherein the oral dosage form contains about 50% to about 90% of the sodium bicarbonate by weight. 11. The method of claim 1, wherein the oral dosage form has the property that 15 minutes after the oral dosage form is added to a simulated gastric fluid, the amount of the meloxicam dissolved in the simulated gastric fluid is greater than the amount of the meloxicam that is dissolved in the simulated gastric fluid as a result of adding an oral reference dosage form to the simulated gastric fluid, wherein the oral reference dosage form contains: 1) the same amount of meloxicam, 2) no rizatriptan, and 3) no bicarbonate. 12. The method of claim 1, wherein the oral dosage form has the property that 15 minutes after the oral dosage form is added to a simulated gastric fluid, the amount of the rizatriptan dissolved in the simulated gastric fluid is greater than the amount of the meloxicam. 13. The method of claim 1, wherein after administering the oral dosage form, the human being experiences pain relief sooner than would be experienced as a result of orally administering a reference dosage form containing: 1) the same amount of meloxicam, 2) the same amount of bicarbonate , 3) the same amount of SBEβCD, and 3) no rizatriptan. 14. The method of claim 1, wherein the oral dosage form has the property that 30 minutes after the oral dosage form is added to a simulated gastric fluid, at least about 50% of the rizatriptan in the dosage form is dissolved in the simulated gastric fluid. 15. The method of claim 1, wherein the oral dosage form has the property that 30 minutes after the oral dosage form is added to a simulated gastric fluid, at least about 50% of the meloxicam in the oral dosage form is dissolved in the simulated gastric fluid. 16. The method of claim 1, wherein the Tmax of meloxicam in the human being after administering the oral dosage form is less than about 1 hour. 17. The method of claim 1, wherein the Tmax of rizatriptan in the human being after administering the oral dosage form is less than about 2 hours.